Last reviewed · How we verify
NCT06134661: ATMSSlowing
Accelerated rTMS for Psychomotor Slowing
NA trial testing cTBS (continuous Theta Burst Stimulation) in Schizophrenia; Psychosis in 25 participants. Terminated before completion.
30 August 2024
Quick facts
| Lead sponsor | University of Bern |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 22 September 2023 |
| Primary completion | 30 August 2024 |
| Estimated completion | 30 August 2024 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- cTBS (continuous Theta Burst Stimulation)
Conditions studied
- Schizophrenia; Psychosis — all drugs for Schizophrenia; Psychosis →
- Schizophrenia and Related Disorders — all drugs for Schizophrenia and Related Disorders →
- Schizo Affective Disorder — all drugs for Schizo Affective Disorder →
- Brief Psychotic Disorder — all drugs for Brief Psychotic Disorder →
Sponsor
University of Bern
Who can join
Adults 18 to 60, any sex, with Schizophrenia; Psychosis or Schizophrenia and Related Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to optimize the treatment of psychomotor slowing in patients with schizophrenia using Transcranial Magnetic Stimulation (TMS). A previous randomized controlled trial indicated that inhibitory stimulation over the supplementary motor area (SMA) once daily over 3 weeks ameliorates psychomotor slowing. In this trial the investigators use a shorter inhibitory protocol called cTBS and to be applied 3 times per day. This should lead to faster treatment response and less burden to patients. The main question the investigators aim to answer are: Can the treatment with cTBS 3 times per day ameliorate psychomotor slowing in schizophrenia over one week? Participants will complete questionnaires on the first and last day of the study. Each day, participants will receive the TMS-treatment. Optionally, participants can receive a cerebral MRI before the study and/or come for an additional day 6 to repeat some of the questionnaires. There is no comparison group. All participants will receive the same treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06134661
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia; Psychosis
Currently open trials in the same condition.
- NCT07084831 — A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment i · Phase 3 · recruiting
- NCT06341517 — Brain Circuitry Therapeutics for Schizophrenia · NA · recruiting
- NCT05550155 — Efficacy of Maintenance Repetitive Transcranial Magnetic Stimulation (rTMS) in Auditory Verbal Hallucinations · NA · recruiting
- NCT05763966 — Uppsala Psychosis Cohort · recruiting
- NCT05858255 — Hjernegym - Effects of Exergaming in Psychosis: a Clinical Intervention Study · NA · recruiting
Other University of Bern trials
Trials by the same sponsor.
- NCT05940662 — Cost Effectiveness of Various Implant Placement Protocols in the Esthetic Zone · Phase 4 · suspended
- NCT02919163 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 6 of 7) · NA · not yet recruiting
- NCT02919189 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7) · NA · not yet recruiting
- NCT04817592 — Characterization of the Corneal Biomechanics of Patients Treated by Corneal Lenticule Extraction for Advanced Refractive · not yet recruiting
- NCT06806150 — The INSPIRE Study: INvestigation of Swiss Physicians Inner-life, Resilience, and Emotions · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06134661 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Bern
- Last refreshed: 25 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06134661.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing